125 related articles for article (PubMed ID: 12473572)
1. Targeting the mitochondria: an exciting new approach to myeloma therapy. Commentary re: N. J. Bahlis et al., Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin. Cancer Res., 8: 3658-3668, 2002.
Dalton WS
Clin Cancer Res; 2002 Dec; 8(12):3643-5. PubMed ID: 12473572
[No Abstract] [Full Text] [Related]
2. Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent.
Amadori S; Fenaux P; Ludwig H; O'dwyer M; Sanz M
Curr Med Res Opin; 2005 Mar; 21(3):403-11. PubMed ID: 15811209
[TBL] [Abstract][Full Text] [Related]
3. Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma.
Wu KL; Beksac M; van Droogenbroeck J; Amadori S; Zweegman S; Sonneveld P
Haematologica; 2006 Dec; 91(12):1722-3. PubMed ID: 17145617
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma.
Hussein MA; Saleh M; Ravandi F; Mason J; Rifkin RM; Ellison R
Br J Haematol; 2004 May; 125(4):470-6. PubMed ID: 15142117
[TBL] [Abstract][Full Text] [Related]
5. New drugs in multiple myeloma.
Berenson JR; Yellin O
Curr Opin Support Palliat Care; 2008 Sep; 2(3):204-10. PubMed ID: 18685422
[TBL] [Abstract][Full Text] [Related]
6. Clinical trials referral resource. Clinical trials with arsenic trioxide.
Murgo AJ; McBee WL; Cheson BD
Oncology (Williston Park); 2000 Feb; 14(2):206, 211, 215-6 passim. PubMed ID: 10736809
[No Abstract] [Full Text] [Related]
7. Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid.
Campbell RA; Sanchez E; Steinberg JA; Baritaki S; Gordon M; Wang C; Shalitin D; Chen H; Pang S; Bonavida B; Said J; Berenson JR
Br J Haematol; 2007 Aug; 138(4):467-78. PubMed ID: 17587338
[TBL] [Abstract][Full Text] [Related]
8. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma.
Bahlis NJ; McCafferty-Grad J; Jordan-McMurry I; Neil J; Reis I; Kharfan-Dabaja M; Eckman J; Goodman M; Fernandez HF; Boise LH; Lee KP
Clin Cancer Res; 2002 Dec; 8(12):3658-68. PubMed ID: 12473574
[TBL] [Abstract][Full Text] [Related]
9. Clinical activity of arsenic trioxide for the treatment of multiple myeloma.
Munshi NC; Tricot G; Desikan R; Badros A; Zangari M; Toor A; Morris C; Anaissie E; Barlogie B
Leukemia; 2002 Sep; 16(9):1835-7. PubMed ID: 12200700
[TBL] [Abstract][Full Text] [Related]
10. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies.
Douer D; Tallman MS
J Clin Oncol; 2005 Apr; 23(10):2396-410. PubMed ID: 15800332
[TBL] [Abstract][Full Text] [Related]
11. Arsenic metabolism in multiple myeloma and astrocytoma cells.
Falnoga I; Slejkovec Z; Pucer A; Podgornik H; Tusek-Znidaric M
Biol Trace Elem Res; 2007 Apr; 116(1):5-28. PubMed ID: 17634624
[TBL] [Abstract][Full Text] [Related]
12. A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma.
Berenson JR; Matous J; Swift RA; Mapes R; Morrison B; Yeh HS
Clin Cancer Res; 2007 Mar; 13(6):1762-8. PubMed ID: 17363530
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of arsenic trioxide for the treatment of relapsed and refractory multiple myeloma: a systematic review.
Röllig C; Illmer T
Cancer Treat Rev; 2009 Aug; 35(5):425-30. PubMed ID: 19464807
[TBL] [Abstract][Full Text] [Related]
14. JWA is required for arsenic trioxide induced apoptosis in HeLa and MCF-7 cells via reactive oxygen species and mitochondria linked signal pathway.
Zhou J; Ye J; Zhao X; Li A; Zhou J
Toxicol Appl Pharmacol; 2008 Jul; 230(1):33-40. PubMed ID: 18387645
[TBL] [Abstract][Full Text] [Related]
15. The incidence of recurrent herpes simplex and herpes zoster infection during treatment with arsenic trioxide.
Nouri K; Ricotti CA; Bouzari N; Chen H; Ahn E; Bach A
J Drugs Dermatol; 2006 Feb; 5(2):182-5. PubMed ID: 16485889
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of melphalan, arsenic trioxide, and ascorbic acid combination therapy (MAC) in relapsed and refractory multiple myeloma.
Borad MJ; Swift R; Berenson JR
Leukemia; 2005 Jan; 19(1):154-6. PubMed ID: 15496977
[No Abstract] [Full Text] [Related]
17. Arsenic trioxide in multiple myeloma: rationale and future directions.
Anderson KC; Boise LH; Louie R; Waxman S
Cancer J; 2002; 8(1):12-25. PubMed ID: 11895198
[TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide: a new immunomodulatory agent in the management of multiple myeloma.
Hussein MA
Med Oncol; 2001; 18(4):239-42. PubMed ID: 11918450
[TBL] [Abstract][Full Text] [Related]
19. Clinical activity of arsenic trioxide in Burkitt-like lymphoma.
Ravandi F; van Besien K
Leukemia; 2003 Jan; 17(1):271-2. PubMed ID: 12529694
[No Abstract] [Full Text] [Related]
20. Arsenic trioxide: new preparation. Acute promyelocytic leukaemia: encouraging results but persistent doubts.
Prescrire Int; 2004 Aug; 13(72):135-7. PubMed ID: 15532137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
